Privately-held Canadian biotech firm Zymeworks has joined forces with Innovative Targeting Solutions (ITS) to strengthen its in-house antibody discovery capabilities.
Under the terms of the collaboration, Zymeworks, which develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases, will in-license and integrate ITS’ proprietary HuTARG platform to help identify and develop therapeutics directed towards challenging disease targets.
This is a protein engineering platform which has been billed as representing a disruptive technology in the field. It is the first fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination, allowing for the generation and affinity maturation of highly potent protein-based biologics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze